![Takashi Owa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Haruo Naito | M | 76 | 49 ans | |
Yasushi Okada | M | 65 | 43 ans | |
Ping Zhu | M | - |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | 12 ans |
Sayoko Sasaki | F | 55 | 33 ans | |
Keisuke Naito | M | 35 | 11 ans | |
Masatomi Akana | M | 57 | 34 ans | |
Tatsuyuki Yasuno | M | 56 | 33 ans | |
Kenta Takahashi | M | 64 | 41 ans | |
Clive Richard Thornley | M | 59 | 2 ans | |
Ryota Miura | M | 50 | 3 ans | |
Lynn Kramer | M | 73 | 15 ans | |
Teruyuki Masaka | M | 46 | 23 ans | |
Yoshiteru Kato | M | 64 | 36 ans | |
Fumihiko Ike | M | 72 | 3 ans | |
Hiroyuki Kato | M | 66 | 42 ans | |
Yumiko Miwa | F | 58 | 4 ans | |
Yasunobu Kai | M | 62 |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
Makoto Hoketsu | M | - | - | |
Mitsuru Shomon | M | - | - | |
Brian Liau | M | - |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
Alexander Scott | M | - |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
Toshitaka Asano | M | 58 | - | |
Toru Moriyama | M | 69 | - | |
Terushige Iike | M | 60 | 38 ans | |
Richard C. Woodman | M | 69 |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | 2 ans |
Shohei Kanazawa | M | 59 | 36 ans | |
Gary Bryan Hendler | M | 57 | 14 ans | |
Yuko Yasuda | F | 62 | - | |
Ivan Cheung | M | 47 | 19 ans | |
Akiko Nakahama | F | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
Pays | Relations | % du total |
---|---|---|
Japon | 70 | 93,33% |
Etats-Unis | 5 | 6,67% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Takashi Owa
- Réseau Personnel